This review aims to summarize the diverse proposed pathophysiological mechanisms
contributing to postpartum depression, highlighting both clinical and basic science research …

Estradiol is the “prototypic” sex hormone of women. Yet, women have another sex hormone,
which is often disregarded: Progesterone. The goal of this article is to provide a …

Ten to twenty percent of postpartum women experience anxiety or depressive disorders,
which can have detrimental effects on the mother, child, and family. Little is known about the …

Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) are common
disorders of the luteal phase of the menstrual cycle and are characterized by moderate to …

Postpartum depression (PPD) is one of the three major categories on the spectrum of
postpartum psychiatric syndromes. Postpartum psychiatric syndromes are classified as …

Postpartum depression (PPD) is a serious health issue that can affect about 15% of the
female population within after giving birth. It often conveys significant negative …

Current evidence is mixed on the role of progesterone and its metabolites in perinatal mood
and anxiety disorders. We measured second and third trimester (T2 and T3) progesterone …

Objective: Concurrent anxiety and/or insomnia symptoms in women with postpartum
depression (PPD) are common and associated with more severe PPD. The effects of …

Objective Preclinical evidence indicates that rapid changes in levels of allopregnanolone,
the predominant metabolite of progesterone, confer dramatic behavioral changes and may …

Recent FDA approval of an allopregnanolone-based treatment specifically for postpartum
depression, brexanolone, now commercially called Zulresso®, is an exciting development …